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MicePrevious studies have suggested that γ-aminobutyric acid-B (GABAB) receptor agonists effectively reduce
ethanol intake. The quantiﬁcation using real-time polymerase chain reaction of Gabbr1 and Gabbr2 mRNA
from the prefrontal cortex, hypothalamus, hippocampus, and striatum in mice exposed to an animal model
of the addiction developed in our laboratory was performed to evaluate the involvement of the GABAB recep-
tor in ethanol consumption. We used outbred, Swiss mice exposed to a three-bottle free-choice model
(water, 5% v/v ethanol, and 10% v/v ethanol) that consisted of four phases: acquisition (AC), withdrawal
(W), reexposure (RE), and quinine-adulteration (AD). Based on individual ethanol intake, the mice were clas-
siﬁed into three groups: “addicted” (A group; preference for ethanol and persistent consumption during all
phases), “heavy” (H group; preference for ethanol and a reduction in ethanol intake in the AD phase com-
pared to AC phase), and “light” (L group; preference for water during all phases). In the prefrontal cortex
in the A group, we found high Gabbr1 and Gabbr2 transcription levels, with signiﬁcantly higher Gabbr1 tran-
scription levels compared with the C (ethanol-naive control mice), L, and H groups. In the hippocampus in
the A group, Gabbr2 mRNA levels were signiﬁcantly lower compared with the C, L, and H groups. In the stri-
atum, we found a signiﬁcant increase in Gabbr1 transcription levels compared with the C, L, and H groups. No
differences in Gabbr1 or Gabbr2 transcription levels were observed in the hypothalamus among groups. In
summary, Gabbr1 and Gabbr2 transcription levels were altered in cerebral areas related to drug taking only
in mice behaviorally classiﬁed as “addicted” drinkers, suggesting that these genes may contribute to high
and persistent ethanol consumption.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Central γ-aminobutyric acid (GABA) neurotransmission is a sensitive
target for both the acute and chronic effects of ethanol (Lovinger, 2008).
Although several studies have investigated the neuroadaptations associ-
ated with ionotropic GABAA receptors after ethanol use (for review, see
Enoch, 2008), the neuroadaptations of metabotropic GABAB receptors
need to be clariﬁed.
Human studies have revealed the efﬁcacy of baclofen (β-
parachlorophenol GABA, a GABAB receptor agonist) in reducing ethanol
intake and the compulsive desire for ethanol in dependent individuals
(Addolorato et al., 2002; Flannery et al., 2004), but no difference was
found in the efﬁcacy of baclofen in other clinical study (Garbutt et al.,ia Geral, ICB–UFMG, Avenida
1, Belo Horizonte, MG, Brazil.
ard).
vier OA license.2010) although recently Muzyk et al. (2012) reported higher rates of ab-
stinence and lower anxiety scores in baclofen-treated patients.
A reduction in ethanol consumption was observed in Sardinian
alcohol-preferring (sP) rats after acute baclofen administration
(Maccioni et al., 2005). Baclofen also suppressed the ethanol depriva-
tion effect in rats exposed to ethanol for 8 weeks (Colombo et al.,
2003a, 2003b). C57BL/6J mice exhibited increased ethanol consump-
tion after repeated baclofen administration (Moore et al., 2007), al-
though baclofen microinjection into the anterior ventral tegmental
area reduced binge-like ethanol intake in the same strain (Moore and
Boehm, 2009).
In summary, baclofen, a GABAB agonist, reduces ethanol intake in
animals and humans, but the contrary or no effect was also reported.
Some authors have demonstrated that conformational alteration
of the GABAB1 subunit and subsequently conformational alteration
of the entire GABAB1–GABAB2 complex is necessary for effective acti-
vation of the GABAB receptor (Morishita et al., 1990). Consequently,
the precise balance between the two subunits is necessary for the
225A.F. Ribeiro et al. / Pharmacology, Biochemistry and Behavior 102 (2012) 224–232activation of the receptor. One question is how this disproportional
receptor subtype expression can support a basis for research on indi-
vidualizing treatment.
A human study showed no signiﬁcant association between
GABBR1 gene polymorphisms and alcoholism (Köhnke et al., 2006).
However, another analysis suggested a possible association between
GABBR1 and some groups of alcoholics (Sander et al., 1999). Recently,
a signiﬁcant association between GABBR1 and GABBR2 and nicotine
dependence was demonstrated in an American sample, suggesting a
possible correlation between these genes and addictive behavior (Li
et al., 2009).
The GABAB receptor comprises two protein subunits, GB1 and
GB2, encoded by the Gabbr1 and Gabbr2 genes, respectively. Although
the Gabbr1 gene has various isoforms, the most widely expressed
isoforms in the central nervous system are Gabbr1a and Gabbr1b,
which are differentiated by the presence of a sequence that codiﬁes
two sushi domains (short consensus repeats, SCR or CPs) in the GB1
protein (Kaupmann et al., 1997; Hawrot et al., 1998).
The GABAB receptor can be found as a heterodimer (GB1a/GB2 or
GB1b/GB2), and both subunits are essential for GABAB function
(Margeta-Mitrovic et al., 2001; Misgeld et al., 1995; Bowery et al.,
2002; Bettler et al., 2004; Jones et al., 1998; Chen and van den Pol,
1998; Filippov et al., 2000). Presynaptically, the GABAB receptor in-
hibits dopaminergic, GABAergic, and glutamatergic systems, and al-
terations in these systems are well known to be associated with
addictive behavior (for review, see Koob et al., 1998; Everitt and
Robbins, 2005; Kalivas and Volkow, 2005; Le Moal and Koob, 2007).
To understand the inﬂuence of genes on ethanol intake, some ro-
dent models that use genetic selection have been used and have con-
tributed to a better comprehension of alcoholism, but their results
have been inconclusive (Green and Grahame, 2008). A question that
arises from the interpretation of studies that involve selective breed-
ing or inbreeding is whether high-drinking lines exhibit greater
ethanol-reinforced behavior than low-drinking lines. Moreover,
some animal studies may lack many aspects of human alcoholism,
such as compulsive drug use, which is characteristic of addiction
and central to the clinical diagnosis of dependence (American
Psychiatric Association, 1994). Addiction is deﬁned as compulsive
drug use despite negative consequences. In recent years, new animal
models have been developed and proposed for the study of compul-
sive drug use (i.e., craving or persistent desire for drug), relapse,
and loss of control, which are speciﬁc components of human addic-
tion (Heyman, 2000; Phillips, 2002; Shippenberg and Koob, 2002;
Spanagel, 2003; Camarini et al., 2010).
The animal model used in the present study was proposed initially
for rats by Wolffgramm and Heyne (1995) and validated for mice in
our laboratory (Fachin-Scheit et al., 2006). We previously demon-
strated the model's reliability, face validity (long-term high ethanol
intake and ethanol preference over 4 months, considering the whole
life of a mouse, and persistent intake despite bitter taste adulteration
of ethanol solutions), and predictive validity (when tested with nal-
trexone as a pharmacological challenge, mice reduced ethanol intake
(Fachin-Scheit et al., 2006; Ribeiro et al., 2008; Correia et al., 2009).
The behavioral analysis of ﬂuid intake in mice exposed to a free-
choice model was accomplished, and two phenotypes exhibited
high ethanol consumption and preference for ethanol during almost
the entire treatment (i.e., great behavioral similarity). During the
last 2 weeks of the model when ethanol was adulterated with qui-
nine, some high-drinker mice signiﬁcantly reduced their ethanol in-
take, whereas others continued to show the same consumption. The
“loss of control over the ingestion of ethanol” suggestive of “addic-
tion” (Spanagel, 2009) can be examined in this model only for some
mice when ethanol solutions are made “less palatable” by the addi-
tion of a quinine solution.
Drug addiction behavior involves different components of the
neuronal circuitry like the prefrontal cortex (related with thereinstatement of drug seeking), hippocampus (recognition of contex-
tual conditioned stimuli associated to the drug), hypothalamus (neu-
roendocrine control), and striatum (related to the drug's rewarding
effects). Each of these areas plays a different role in functions related
to addictive behavior (for review, see Kalivas and Volkow, 2005;
Everitt and Robbins, 2005), with different transcription and protein
proﬁles.
Considering (i) the participation of GABAB receptors in ethanol con-
sumption; (ii) the reduction in ethanol consumption under baclofen
treatment; (iii) the increase in Gabbr2 protein in nicotine addiction;
(iv) the differential participation of brain structures in the neurobiolo-
gy of drug-taking behavior; and (v) our validated ethanol consumption
model provides an alternative approach to the study of addictive be-
haviors and to the individual ethanol intake proﬁles, we hypothesized
that “addicted” mice might have an increase in Gabbr1 and Gabbr2
transcription levels in those brain areas related to addictive behavior
when compared to non-addicted mice (heavy-drinking and light-
drinking mice). Thus, the increased GABAB activity would lead to
greater inhibition in dopamine release in nucleus accumbens, increas-
ing the rewarding value of ethanol for those mice due to the increased
ethanol-induced dopamine release by other mechanisms.
2. Materials and methods
2.1. Animals
Eighty naive 6-week-old Swiss male mice that weighed 20–30 g
from the Universidade Federal do Paraná were used in this study.
The mice were housed individually (20×30×20 cm) under a 12 h/
12 h light/dark cycle (lights on at 07:00 h) and controlled tempera-
ture (22 °C±2 °C), with ad libitum access to food (Purina Laborato-
ries, Curitiba, Brazil). One week before the treatments, the mice
underwent an acclimation period, and water intake and body weight
were measured. All procedures were performed during the light
cycle. Experimental care and treatment were approved by the Ethics
Committee for Animal Experimentation of the Setor de Ciências Bio-
lógicas (Protocol Number: 281), Universidade Federal do Paraná.
2.2. Experimental design
2.2.1. Extended chronic ethanol intake
One group of mice (n=60) was exposed to three-bottle free-
choice treatment for 10 weeks (acquisition [AC] phase), during
which they had free access to both 10% and 5% (v/v) ethanol and
water. Another group of control animals (n=20) only had access to
water during all phases of the experiment. The experimental design
is summarized in Fig. 1. The positions of the bottles were changed
on alternate days when ﬂuid intake was measured volumetrically.
Over the next 2 weeks, only water was provided [withdrawal (W)
phase]. For the following 2 weeks, the ethanol solutions were again
offered to establish free-choice responding among the ethanol solu-
tions and water [reexposure (RE) phase]. At the end of this period,
the ethanol solutions were adulterated with 0.005 g/L quinine,
which produces a bitter-tasting solution, and offered to the animals
for a further 2 week period [adulteration (AD) phase]. This quinine
concentration was chosen through an analysis of dose–response
using other mice, in which the 0.005 g/L concentration of quinine sig-
niﬁcantly reduced its intake compared with water intake without
completely inhibiting response (Fachin-Scheit et al., 2006), suggesting
an “aversive-like” effect. This dose–response analyze was based
on daily administration of different quinine concentration to different
groups of mice (n=10 per concentration) during seven days. The
water and quinine solution consumptions (mL) were performed after
24 h (Table 1).
At the end of the exposition to the 3-bottle free choice paradigm,
the mice were classiﬁed into groups based on their individual
Fig. 1. Experimental design. Methods for assessing loss of control over ethanol ingestion inmice (Correia et al., 2009; Fachin-Scheit et al., 2006). The intake model runs for 16 weeks and
is divided into four phases. Over the course of a 10 week period (acquisition phase), experimental mice have a free choice among 0% (i.e., water vehicle), 5%, and 10% ethanol. Control
animals have access only to water. After this period, ethanol solutions are removed for 2 weeks (withdrawal phase), and mice have access only to water. The ethanol solutions are then
offered again for 2 weeks (reexposure phase). In the ﬁnal 2 weeks phase (adulteration phase), ethanol solutions are adulterated with quinine hydrochloride (0.005 g/L).
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ed the preference between total ethanol intake (mL) and water con-
sumption during each phase for each mouse. Those mice preferring
water during all phases were classiﬁed as “light-drinker” (group L).
Those mice preferring ethanol during AC were, then, evaluated re-
garding their individual ethanol consumption (g/kg/day) along the
phases: those ones maintaining [i.e., no signiﬁcant decrease] the eth-
anol intake when ethanol solutions were added quinine (AD phase)
were classiﬁed as “addicted” (group A); and those ones with de-
creased ethanol consumption during the AD phase compared to AC
phase were classiﬁed as “heavy-drinker” (group H). The animals
that did not conform strictly to any of these patterns were excluded
from subsequent analyses (Table 2).
2.2.2. Molecular analysis
At the end of the free-choice ethanol experiment (week 17), mice
were euthanized by decapitation, and four brain regionswere dissected
on ice: prefrontal cortex, hypothalamus, hippocampus, and striatum
(the latter two from both hemispheres; Paxinos and Franklin, 2001).
The structures were conditioned in 1 mL RNAlater® (Ambion-Qiagen,
São Paulo, Brazil) and then frozen at−80 °C. All mice had continuous
free-choice access to ethanol until decapitation.
For the RNA extraction, the samples immersed in RNAlater® were
thawed, and total RNA was extracted using TRizol® according to the
manufacturer's protocol (Invitrogen, São Paulo, Brazil). Samples
were quantiﬁed using NanoDrop® ND-1000v3 1.0 (Thermo FisherTable 1
Effect of different quinine concentrations on ﬂuid intake.
Quinine concentration (g/L)
0.001 0.005 0.01 0.05
Day Fluid choice Fluid intake (mL/day)
1 Quinine 3.2±0.61 2.8±0.63 1.6±0.43*** 1.3±0.39***
Water 3.6±0.56 4.4±0.76 4.6±0.60 6.7±0.67
2 Quinine 2.6±0.62 1.8±0.76* 1.8±0.59** 0.7±0.30***
Water 3.4±0.54 4.0±0.80 5.2±0.76 6.8±0.68
3 Quinine 2.6±0.62 2.4±0.62* 0.5±0.22*** 1.0±0.47***
Water 4.0±0.60 4.6±0.86 5.8±0.25 6.2±0.55
4 Quinine 1.8±0.32*** 0.5±0.22*** 1.4±0.37*** 0.6±0.22***
Water 4.1±0.46 6.0±0.52 5.8±0.57 6.6±0.70
5 Quinine 2.7±0.76 1.9±0.84* 0.6±0.22*** 0.6±0.22***
Water 3.4±0.64 4.5±0.87 6.3±0.49 6.5±0.65
6 Quinine 2.9±0.71 2.2±0.69* 0.9±0.10*** 0.9±0.18***
Water 3.7±0.65 4.7±0.92 6.3±0.52 6.9±0.60
7 Quinine 2.5±0.85 1.7±0.67** 1.1±0.10*** 1.3±0.26***
Water 4.6±0.76 5.2±0.87 6.0±0.54 6.4±0.58
Daily ﬂuid intake during a 1 week period based on a choice between water and a bitter-
tasting solution containing different concentrations of quinine. Data are expressed as
mean±SEM for different groups of mice for each quinine concentration (n=10 per
concentration). *p≤0.05, **p≤0.005, ***p≤0.001, signiﬁcant difference between qui-
nine and water intake for each day and each concentration (Student's t-test for inde-
pendent samples).Scientiﬁc, Waltham, MA, USA), and RNA integrity was visualized in
1% agarose gel stained with ethidium bromide. The minimum accept-
able 260/280 nm ratio was 1.7.
The reverse transcription was performed in a total volume of 20 μL
using 2 μg of total RNA and oligo (dT20) primers (Prodimol Bio-
tecnologia, Belo Horizonte, Brazil). SuperScriptIII® (Invitrogen, São
Paulo, Brazil) was used according to the manufacturer's protocol.
To the Real-time PCR, the reactions were performed in a Rotor-
Gene 3000 (Corbett Life Science, Concord, Australia) utilizing SYBR®
Green PCR Master Mix (Applied Biosystems, São Paulo, Brazil). Poly-
merase chain reaction (PCR) ampliﬁcation was performed without
the extension step (95 °C for 10 min, followed by 40 cycles of 95 °C
for 15 s and 60 °C for 60 s). Fluorescence acquisition was measured
in the last step of each cycle (60 °C).
Data were analyzed using RG-3000 (Corbett Life Science) software
and a Microsoft Excel spreadsheet. The minimum acceptable correla-
tion coefﬁcient was 0.90. In all reactions, a negative control without
sample was tested. Melting curves were examined to guarantee the
absence of any spurious products. To normalize mRNA levels, three
reference genes (Gapdh, glyceraldehyde 3-phosphate dehydrogenase;
B-act, β-actin; Ppia, peptidylprolyl isomerase A) were used, and the
relative quantity (Vandesompele et al., 2002) was calculated for the
Gabbr1 and Gabbr2 genes.
2.2.3. Primer design
Exon sequences were obtained from the National Center for Biotech-
nology Information database (http://www.ncbi.nlm.nih.gov; accessed
August 12, 2011). Primer sequences were designed using Primer3
v.0.4.0 (Rozen and Skaletsky, 2000), and the quality and speciﬁcity of
the primer pairs were examined using NetPrimer (http://www.
premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html; accessed
August 12, 2011) and Primer-BLAST (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/index.cgi?LINK_LOC=BlastHome; accessed August
12, 2011), respectively. All primers were positioned in inter-exon re-
gions. Although it was not possible to distinguish among the different
isoforms of the Gabbr1 gene, the isoforms most widely expressed in
the central nervous system, Gabbr1a and Gabbr1b, were covered by
selecting a primer pair which anneals to both isoforms. Primers were
synthesized by Prodimol (Prodimol Biotecnologia, Belo Horizonte, Bra-
zil). The primers had the following sequences: Gabbr1F, 5′-TCC-
ACCAACAACAATGAGGA-3′; Gabbr1R, 5′-GATGGCGCAGTTCAGAGAC-3′;
Gabbr2F, 5′-GAGGACATCAACTCCCCAGA-3′; and Gabbr2R, 5′-CTGGCT-
GTAGGGCTGACAC-3′. For the reference genes, primer sequences were
designed and tested as previously described (Bibancos et al., 2007).
2.3. Blood ethanol concentration (BEC)
Fifty microliter microcapillary tubes were used to collect retro-
orbital blood samples at the end of the experiment (at the end of
the AD phase), during the light cycle, after mice from A, H and L
Table 2
Individual ethanol intake of each group proﬁle.
Phases Analysis
Acquisition Reexposure Adulteration ANOVA t-test
Group Mouse EtOH EtOH EtOH F2,22 P H2O t
A #21 7.4*–0.7 11.7*–0.9 14.7*–0.9 18.75 0.0001 4.7+–0.3 −5.25
#22 10.7–0.5 10.0–0.4 11.7–0.8 2.44 0.11 3.4+–0.2 −16.10
#23 6.3*–0.4 10.5–0.8 11.7–0.9 13.40 0.001 4.0+–0.2 −5.92
#27 11.1–0.4 10.9–0.5 10.5–0.6 0.91 0.42 2.8+–0.3 −17.49
#53 7.6–1.0 10.6–0.8 14.6*–1.5 6.72 0.005 5.9+–0.4 −4.77
#56 13.0–0.6 10.9–0.5 12.1–1.0 1.47 0.25 2.5+–0.2 −17.05
#77 7.5–0.5 8.5–0.7 7.1–0.8 1.24 0.31 3.8+–0.2 −8.61
H #25 11.4*–1.0 8.4–0.5 8.7–0.8 5.63 0.01 4.3+–0.3 −7.49
#36 18.2*–0.6 10.0–0.9 9.7–0.7 33.96 0.0001 4.1+–0.6 −5.71
#59 13.5*–0.9 8.5–0.7 8.6–0.7 8.09 0.002 5.4+–0.4 −6.03
#60 14.8*–0.8 10.0–0.8 10.1–1.2 6.29 0.01 5.2+–0.3 −7.41
#66 17.8*–1.2 11.1–1.0 14.0–1.8 7.14 0.004 5.7+–0.5 −6.13
#76 8.3⁎–0.6 6.1–0.5 6.7–0.8 5.93 0.009 4.7+–0.3 −4.83
#79 14.7*–0.8 8.8*–0.4 11.2*–0.9 15.40 0.0001 2.5+–0.2 −15.44
L #11 7.2–0.6 5.2*–0.3 8.1–0.8 4.03 0.03 8.2+–0.2 7.15
#30 5.4–0.4 6.8–0.4 8.2&–0.7 4.63 0.02 7.7+–0.2 2.35
#31 3.5–0.6 3.4–0.2 3.1–0.4 0.17 0.85 9.4+–0.3 17.06
#38 3.3*–0.4 5.2–0.3 4.7–0.5 6.00 0.008 3.8+–0.3 2.26
#43 1.8–0.3 2.5–0.5 2.2–0.4 0.29 0.75 6.1+–0.2 16.96
#45 2.4–0.3 3.0–0.3 3.0–0.6 0.87 0.43 6.3+–0.2 9.91
#49 4.8–0.5 5.0–0.5 7.0–1.1 1.98 0.16 7.8+–0.2 4.59
#51 5.2–0.6 6.2–0.4 7.5–1.0 1.57 0.23 7.7+–0.2 5.37
Individual's analysis of ethanol intake during the experimental phases (considering the last 2 weeks of the acquisition phase, and the reexposure and adulteration phases). Values
represent means and SEM of ethanol intake (g/kg/day) and water intake (mL/day). Symbols represent signiﬁcant differences for each animal: *pb0.05, different from the other
phases (repeated-measures ANOVA followed by Newman–Keuls post hoc test); &pb0.05, different from the acquisition phase (one-way ANOVA followed by Newman–Keuls
post hoc test); +pb0.05, difference between ethanol and water intake (t-test). EtOH, ethanol; H2O, water. Animals: L, light drinkers; H, heavy drinkers; A, addicted drinkers.
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allow the return to their previous intake proﬁles. Samples were cen-
trifuged and plasma was decanted and stored at −80 °C until the
BEC determination. BEC was achieved using an Analox Alcohol Ana-
lyzer (Analox Instruments, Lunenburg, MA).
2.4. Statistical analysis
Datawere analyzed for distribution normality using the Kolmogorov–
Smirnov test and homogeneity of variance using Levene's test. Body
weight in grams and ethanol intake in milliliters were used to compute
the grams of ethanol intake per kilogram of body weight (g/kg). Ethanol
and water consumption were expressed as the daily mean and stan-
dard error. To classify each mouse accordingly to its ethanol intake
pattern we considered the individual preference between total
ethanol intake (mL) and water intake and also, the individual ethanol
consumption in g/kg/day in each phase: ﬁrstly, the preference between
water and total ethanol intake (mL) in each phase was detected
through t-test for each mouse, then, ANOVA analysis with repeated
measures followed by the Newman–Keuls multiple range post hoc
test for each animal to compare individual consumption throughout
the phases by considering the daily consumption for each phase (i.e.,
14 measures in the AC phase, 14 measures in the RE phase, and 14
measures in the AD phase). The individual data and respective analyses
used for classiﬁcation regarding each mouse are presented here in
Table 2.
After the classiﬁcation of mice into three groups (A, H, and L), the
ANOVA followed by the Newman–Keuls test was used to compare the
groups and phases for ethanol consumption (g/kg/day).
The normalized relative quantity of mRNA was compared using
one-way ANOVA followed by the Newman–Keuls post hoc test for
each brain area in all groups. Within each group, an independent
t-test was used to compare the mRNA levels of the Gabbr1 and
Gabbr2 genes. Both GABA-B receptor subunits' mRNA values were
compared and normalized to the control genes. Values of pb0.05
were considered statistically signiﬁcant. Analyses were performedusing STATISTICA 6.1 software (StatSoft, Sao Caetano do Sul, Brazil).
BEC data were expressed as mg/mL of ethanol and were analyzed
by ANOVA followed by Tukey's test. All analyses were performed
using STATISTICA 6.1 software (StatSoft, Sao Caetano do Sul, Brazil).
Differences were considered signiﬁcant at p≤0.05.
3. Results
3.1. Extended chronic ethanol
3.1.1. Group classiﬁcation based on individual consumption
Mice that were exposed to the free-choice paradigm were classi-
ﬁed into three groups according to their individual water or ethanol
drinking patterns: “addicted” (A group, n=13), “heavy” (H group,
n=11), and “light” (L group, n=21). Three animals were excluded
during the dissection procedure, one died, and the other eleven did
not meet the classiﬁcation criteria (e.g., one mouse preferred water
during the AC phase and ethanol during the AD phase). These animals
were not included in the subsequent analyses.
Animals from the A and H groups consumed more ethanol (g/kg)
than animals from the L group during all phases (FAC(2,25)=42.32,
pb0.0001; FRE(2,25)=45.24, pb0.0001; FAD(2,25)=15.82, pb0.0001).
In the RE phase, the H group exhibited signiﬁcantly lower ethanol
consumption than the A group (pb0.05). During the AC phase, the
H group consumedmore ethanol than the A group (pb0.05). Compar-
isons among phases showed that the H group exhibited signiﬁcantly
lower ethanol intake throughout the phases subsequent to withdraw-
al (pb0.001), whereas the A group showed a constant rate of con-
sumption (F4,50=19.22, pb0.0001). The L group exhibited low
ethanol intake during all phases, and no differences were observed
(Fig. 2).
No difference in water intake (mean mL/day and SEM) was ob-
served among the different groups during the acclimation period
prior to exposure to the free-choice model (C, 6.7–0.48; L, 6.1–0.32;
H, 7.1–0.9; A, 6.3–0.48; F3,28=0.72943, p>0.05). The L group con-
sumed signiﬁcantly more water than the A and H groups, but one-
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ing all phases (C, 8.3–0.45; L, 7.0–0.73; H, 3.2–0.67; A, 3.7–0.69,
FAC(3,28)=21.232, pb0.0001; C, 8.4–0.32; L, 7.4–0.56; H, 5.1–0.50; A,
3.9–0.27 l; FRE(3,28)=19.777, pb0.0001; C, 8.7–0.67; L, 7.5–0.61; H,
5.2–0.57; A, 4.4–0.40; FAD(3,28)=12.549, pb0.0001). No difference
was observed among groups during the withdrawal phase.
3.2. Molecular analysis
Only material that was in good condition was used for the molec-
ular analysis, consisting of 6–8 control mice, 7–8 L mice, 6–7 H mice,
and 5–7 A mice.
One-way ANOVA revealed a group effect for the Gabbr1 gene
(F3,24=5.67, pb0.01) in the prefrontal cortex. The post hoc compari-
son showed that the A group had increased mRNA levels compared
with the other groups. The t-test revealed no signiﬁcant differences
for each group for the levels of Gabbr1 and Gabbr2 transcripts (Fig. 3).
In the hippocampus Gabbr2 transcription levels were lower in the
A group compared with the other groups (F3,23=3.87, pb0.05). A sig-
niﬁcant difference was found between the transcription levels of the
Gabbr1 and Gabbr2 genes only in the A group (t=2.93, pb0.05;
Fig. 3).
No difference was observed in mRNA levels among groups
(Gabbr1: F3,26=0.70, p>0.05; Gabbr2: F3,23=1.18, p>0.05) in the
hypothalamus. For the A, H, and L groups, Gabbr1 transcription levels
were signiﬁcantly higher than Gabbr2 transcription levels (LD:
t=4.00, pb0.05; HD: t=2.12, pb0.05; PH: t=2.57, pb0.05). A simi-
lar proﬁle was observed in the C group, but the difference was not sig-
niﬁcant (Fig. 3).
Comparisons among groups revealed increased Gabbr1 transcrip-
tion levels in the A group (F3,23=4.40, pb0.05) and no difference in
Gabbr2 transcription levels (F3,23=1.05, p>0.05) in the striatum.
All groups exhibited Gabbr1 mRNA levels that were higher than
Gabbr2 mRNA levels, but the difference was signiﬁcant only in the A
group (t=4.00, pb0.05; Fig. 3).
3.3. Blood ethanol concentration (BEC)
BEC values were expressed as mean (mg/mL) and standard devia-
tion for each group: group A (1.13±0.32), group H (0.79±0.56) andFig. 2. Analysis of ethanol intake during the experimental phases (considering the last
2 weeks of the acquisition phase and the reexposure and adulteration phases). Bars
represent mean and SEM of ethanol intake (g/kg/day). *pb0.05, different from the
other phases in the same group (repeated-measures ANOVA followed by Newman–
Keuls post hoc test); #pb0.05, different from the other groups in the same phase
(one-way ANOVA followed by Newman–Keuls post hoc test); &pb0.05, different
from the A group in the same phase (one-way ANOVA followed by Newman–Keuls
post hoc test). EtOH, ethanol. Phases: AC, acquisition; RE, reexposure; AD, adulteration.
Only animals selected to molecular analysis are represented: L, light drinkers; H, heavy
drinkers; A, addicted drinkers.group L (0.48±0.42). ANOVA followed by Tukey's test showed that
group A presented higher BEC than group L (F2,20=3.80, pb0.05).
4. Discussion
The main ﬁnding from the present study was the conﬁrmation of
the proposed hypothesis that “addicted” mice would have high
Gabbr1 and Gabbr2 transcription levels in brain areas related to addic-
tive behaviors. Indeed, mice behaviorally classiﬁed as “addicted”
drinkers (A group) have higher Gabbr1 transcription levels compared
with the C (ethanol-naive control mice), L, and H groups in the pre-
frontal cortex and in the striatum. In the hippocampus, the A group
showed lower Gabbr2mRNA levels than the C, L, and H groups. In sum-
mary, Gabbr1 and Gabbr2 transcription levels were altered in cerebral
areas related to drug taking only in mice behaviorally classiﬁed as
addicted drinkers, suggesting that these genes may contribute to high
and persistent ethanol consumption despite “aversive” condition.
4.1. Animal model
Gabbr1 and Gabbr2 transcription can be found altered to a greater
or lesser degree depending on the speciﬁc central nervous system re-
gion (Misgeld et al., 1995; Bettler et al., 2004). Here, we raised the hy-
pothesis that ethanol consumption observed in the present study,
which are phenotypic manifestation, may have been related to geno-
typic differences among groups. We demonstrated that the genes
that encode the GABAB1 and GABAB2 subunits were differentially
expressed in mice that exhibited a “addicted” proﬁle just in brain
areas which have been proposed by many authors (Kalivas and
Volkow, 2005; Everitt and Robbins, 2005) to be related to addictive
behavior. The animals from group A compared to the other two
groups: had higher Gabbr1 and Gabbr2 transcription levels in the pre-
frontal cortex; lower Gabbr2 mRNA levels in the hippocampus and
higher Gabbr1 transcription levels in the striatum. How these differ-
ences in transcription levels may account for differences in ethanol
consumption is still unknown.
Despite the inherent limitations of any animal model that pro-
poses to mimic addiction, the present model has already been dem-
onstrated to be a reliable model because it reﬂects the “natural
development” of ethanol consumption (Wolffgramm and Heyne,
1995) and provides stable classiﬁcation criteria based on individual
analysis like diagnosis in humans. The model incorporates a “natural”
development in the progression from initiation to “loss of control” of
ethanol consumption, which is observed only in some individuals,
like seen in humans too. We previously demonstrated the model's re-
liability, which was replicated 10 times, and the same proportions of
mice that exhibited the differential intake proﬁles were always
found (about 18 to 25% are group A; 18 to 30% are group H and 28
to 35% are group L). The model has proven face validity (long-term
high ethanol intake, heightened anxiety during ethanol withdrawal
and persistent intake despite adulteration of ethanol solutions with
quinine) and also, has predictive validitywhen tested with naltrexone
as a pharmacological challenge (Camarini et al., 2010; Correia et al.,
2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008). One limitation
to be considered in this study is the lack of positive control regarding
the aversiveness of quinine. One might consider testing the prefer-
ence between quinine-containing alcohol solution versus alcohol so-
lution aiming to discard some preference for quinine adulterated
solutions in each group, although quinine is known to be a bitter-
tasting substance that produces a strong aversion in rodents
(Aravich and Sclafani, 1980). However, this limitation does not com-
promise the validity and reliability of the model.
Wolffgramm and Heyne (1995) suggested that exposing the ani-
mal to “aversive” phases (i.e., withdrawal and adulteration) allows
the assessment of voluntary intake after and under unpleasant condi-
tions. Unlike in rat studies (Spanagel and Hölter, 1999; Wolffgramm
Fig. 3. GABAB receptor genes in speciﬁcs brain areas. Bars represent mean±SEM of Gabbr1 (br1) and Gabbr2 (br2) gene transcripts for each group. Prefrontal cortex (C, n=8;
L, n=7; H, n=6; A, n=7). Hippocampus (C, n=6; L, n=8; H, n=6; A, n=7). Hypothalamus (C, n=8; L, n=8; H, n=6; A, n=5). Striatum (C, n=7; L, n=8; H, n=7;
A, n=5). *pb0.05, signiﬁcantly different from the other groups (one-way ANOVA followed by Newman–Keuls post hoc test); #pb0.05, signiﬁcantly different from the other
gene in the same group (independent t-test). Both GABA-B receptor subunits mRNA values were compared and normalized to the control genes. Animals: C, controls; L, light
drinkers; H, heavy drinkers; A, addicted drinkers.
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crease in ethanol consumption after withdrawal (ethanol deprivation
effect). Moreover, the A group showed no preference for either of the
two concentrations of ethanol solutions, although when assessed in-
dividually, some mice preferred one solution over the other during
all phases. Perhaps some characteristics of the mouse strain utilized
in the present study inﬂuenced the manifestation of these behaviors.
Nevertheless, preference and high ethanol intake did not vary be-
tween phases, indicating a persistent neuroadaptation related to
such behaviors in animals with impaired control on ethanol intake.
Additionally, the model incorporates the “natural” progression from
the initiation of ethanol consumption to persistent ethanol consump-
tion despite the bitter taste (which may be indicative of “loss of con-
trol,” a hallmark of addictive behavior in humans) using outbred
mice.
Animals classiﬁed as heavy drinkers (H group) exhibited high eth-
anol preference during the acquisition phase and a signiﬁcant reduc-
tion in ethanol consumption after the withdrawal phase, suggesting
that adaptations developed during acquisition did not induce persis-
tent ethanol consumption.
The difference between the A and H groups was persistent ethanol
intake during the adulteration phase (i.e., no signiﬁcant reduction in
ethanol consumption in this phase, reﬂected by intra-group compari-
sons in the A group). No difference was found in voluntary ethanol in-
take during this phase between these groups (i.e., reﬂected by inter-group comparisons). Thus, we suggest that molecular differences may
result from innate susceptibility to the effects of ethanol (i.e., individual
variations). The ethanol consumption in the “addicted”mice (A group)
reached 9.5±0.8 g/kg/day in the AC phase and 11.4±0.9 g/kg/day in
the AD phase, whereas ethanol consumption in the light-drinker mice
(L group) reached 4.2±0.5 g/kg/day and 5.7±0.7 g/kg/day, respec-
tively. Heilig and Koob (2007) mentioned that laboratory rodents do
not voluntarily consume ethanol to the point of intoxication, and
even when masking the taste of ethanol with a sweetener, which
is faded out as ethanol concentrations are increased, rats that have
not been bred for high ethanol preference rarely consume more than
2 g ethanol/kg/day, and blood ethanol concentrations required for
dependence are rarely achieved. However, some genetically rodent
lines under certain conditions (Crabbe et al., 2009; Murphy et al.,
2002; McBride and Li, 1998) voluntarily exceed BECs of 100 mg%,
which is considered an intoxication level. In our present study, we
observed that “addicted” mice exhibited average BEC above this limit,
i.e. 113 mg%.
Mice classiﬁed as light drinkers (L group) showed no changes in
ethanol intake across the experimental phases. These mice exhibited
water preference and low ethanol consumption. Indeed, even under
stressful situations (e.g., isolation, ethanol exposure and withdrawal),
these animals did not develop ethanol preference, in contrast to the A
and H groups. Thus, mice in the L group may present behavioral and
biological features that prevent the manifestation of behaviors that
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ethanol intake). We may also consider that this group is a possible
control for the free-choice experiment.
4.2. Transcriptional proﬁle of Gabbr1 and Gabbr2 genes
Our results demonstrated that the transcriptional proﬁles of
GABAB receptor genes were different depending on the brain area an-
alyzed. Each of these areas plays a different role in functions related to
addictive behavior (for review, see Kalivas and Volkow, 2005; Everitt
and Robbins, 2005), with different transcription and protein proﬁles.
Chemical sensitivity tends to be distinct among cerebral areas. The
prefrontal cortex and striatum may be considered less sensitive to
ethanol compared with other regions. However, the possibility that
the transcription levels of both genes might indeed decrease in re-
sponse to continued stimulus exposure, similar to the hippocampus,
cannot be excluded.
The discrepancies between Gabbr1 and Gabbr2mRNA levels in the
hypothalamus and striatum, and the linearity between these tran-
scripts in the prefrontal cortex and hippocampus are consistent
with other observations in rats and humans (Jones et al., 1998;
Clark et al., 2000; Berthele et al., 2001; Martin et al., 2004). However,
our results demonstrated a more pronounced difference between
Gabbr1 and Gabbr2 mRNA levels in the hippocampus and striatum,
which could reﬂect a possible alteration in the transcriptional homeo-
stasis (i.e., disequilibrium) of these genes in the A group.
An increase in mRNA levels of both genes was observed in the pre-
frontal cortex, and was signiﬁcant for Gabbr1 in the A group. An anal-
ysis of the brains of alcoholic humans revealed an increase in GABBR1
transcription levels compared with control subjects (Flatscher-Bader
et al., 2005). The prefrontal cortex is involved in decision making
(Bush et al., 2002) and plays an important role in the transition
from voluntary actions to compulsion to drug addiction (for review,
see Everitt and Robbins, 2005). Moreover, the prefrontal cortex is as-
sociated with the response to predictability of rewarding stimuli
(Berns et al., 2001). The signiﬁcant increases in transcription levels
in the prefrontal cortex observed only in the A group could be related
to the “loss of control” over ethanol intake because if this increase is
observed equally in all mice, one can conclude that this is an
ethanol-induced effect.
The hippocampus is associated with the motivational impact of
contextual stimuli on drug seeking (for review, see Everitt and
Robbins, 2005). Hippocampal glutamatergic afferents to the nucleus
accumbens modulate the increases in mesoaccumbens dopamine re-
lease and therefore can inﬂuence responses that are mediated by lim-
bic structures (Floresco et al., 2001). In contrast to the observations in
the prefrontal cortex in the present study, a reduction in Gabbr1 and
Gabbr2 transcription levels was observed in the hippocampus,
reaching signiﬁcance for the latter gene in the A group. A study that
utilized rats subjected to chronic ethanol treatment found a reduction
in GABA release, an effect possibly modulated by presynaptic GABAB
receptors in the hippocampus (Peris et al., 1997). Other studies
have demonstrated that ethanol facilitates the function of presynaptic
GABAB receptors in the CA1 area of the hippocampus (Frye and
Fincher, 1996; Wan et al., 1996; Ariwodola and Weiner, 2004). How-
ever, in a study that used rats exposed to chronic cocaine treatment,
GABAB receptor desensitization was found after 3 drug-free weeks.
Furthermore, GABAergic tone increased, suggesting a possible loss
of presynaptic GABAB receptor activity (Xi et al., 2003). Although
the role of GABAB receptors in addictive behavior is still unclear, al-
tered activity of this receptor may interfere with glutamatergic and
dopaminergic circuits in this brain region, which may have contribut-
ed to the maintenance of the drug-taking behavior observed in our
mice that exhibited persistent ethanol consumption.
The A group exhibited higher Gabbr1 mRNA levels in the striatum
compared with the other groups. Previous studies have demonstratedthat increases in dopamine in the striatum in humans are associated
with the reinforcing effects of stimulants (for review, see Kalivas
and Volkow, 2005), suggesting that the increase in dopamine levels
might be more related to the motivation to obtain the drug than to
the pleasure evoked by the drug. Gabbr1 knockout mice showed in-
creased extracellular dopamine levels in the striatum, and the release
of these neurotransmitters was lower in knockouts than in wildtype
mice after D-amphetamine administration (Vacher et al., 2006).
These results suggest that GABAergic tone might be important for
the maintenance of dopaminergic circuit homeostasis involved in
drug-taking behavior.
Although the hypothalamus has considerable concentrations of
Gabbr1 and Gabbr2 transcripts, no signiﬁcant changes were found
among the groups of ethanol consumers. This brain region regulates
ingestive behaviors and has projections to limbic structures. Further-
more, hypothalamic function plays an important role in disorders re-
lated to ethanol use.
Regardless of the GABAergic inﬂuence on glucose metabolism,
we found no differences in the mRNA levels of glyceraldehyde 3-
phosphate-dehydrogenase (i.e., the reference gene) in any of the
areas analyzed, which is consistent with Eravci et al. (1999). However,
other studies have found altered gene expression related to glucose
metabolism in the hippocampus in alcoholic humans (Matsuda-
Matsumoto et al., 2007) and altered transcription levels in the hippo-
campus of animals after chronicle ethanol consumption (Hargreaves
et al., 2009). Further studies are necessary to clarify the cross-talk be-
tween these systems and their relationships with ethanol addiction.
Interestingly, light-drinker mice (L group) demonstrated no alter-
ations in Gabbr1 and Gabbr2 mRNA levels, and their transcriptional
proﬁles were similar to the control group. This phenotype, therefore,
may provide useful information about possible protector genes and
may thus help us understand the mechanisms that underlie the pre-
vention of disorders related to excessive ethanol intake.
Establishing a direct association between transcription and gene
expression is difﬁcult. Therefore, a simple increase or decrease in spe-
ciﬁc mRNAs may not represent a direct gene effect on the phenotype.
Moreover, we cannot be sure if the purported differences in gene ex-
pression existed before ethanol drinking, are a consequence of such
drinking, or are consequence of some combination of both. These
data reﬂect a possible association between Gabbr1 and Gabbr2
genes and the loss of control of ethanol intake. However, such
disturbances could indicate that transcriptional homeostasis in
the brain is related to the maintenance of persistent drug-taking
behavior in these mice. Thus, continuous stimuli that alter tran-
scription levels or the genetic transcription of a speciﬁc isoform
can inﬂuence the regulatory mechanisms of gene expression (e.g.,
by non-coding RNAs that alter alternative splicing) and conse-
quently interfere with synaptic plasticity (Huang et al., 2005; Li
et al., 2007). Understanding these modulatory mechanisms will
aid in better comprehending the neural control of persistent ethanol
consumption.
Based on the present results, Gabbr1 and Gabbr2 transcript levels
were altered in cerebral areas crucially related to drug-taking behav-
ior only in mice phenotypically classiﬁed as addicted drinkers. In this
sense, we conducted an experiment to determine the effect of a
GABAB agonist in these animals considering a model of human addic-
tion, a good model to assess individual responses to a given treat-
ment. Nevertheless, additional studies are necessary to clarify the
regulatory mechanisms that may interfere with gene transcription
and consequently the conservation of high and persistent ethanol
intake.
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